---
title: "北京福元醫藥股份有限公司 (601089.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/601089.SH.md"
symbol: "601089.SH"
name: "北京福元醫藥股份有限公司"
industry: "制藥"
---

# 北京福元醫藥股份有限公司 (601089.SH)

| Item | Detail |
|------|--------|
| Industry | 制藥 |
| Location | 滬深市場 |
| Website | [www.foyou.com.cn](https://www.foyou.com.cn) |

## Company Profile

公司 2022 年 6 月 30 日上市。公司以 “專注醫藥領域，共創健康人生” 為使命，致力于打造研發、生產、銷售三位一體的核心競爭優勢，持續打造規模化產品群，形成 “領域、品種、技術” 組合優勢的豐富產品線，構建從原料到藥品完整週期的產業價值鏈。公司主要從事藥品制劑及醫療器械的研發、生產和銷售。主要產品有奧美沙坦酯片、替米沙坦片、鹽酸曲美他嗪片、阿托伐他汀鈣片、哈西奈德溶液、匹維溴銨片、開塞露、強力枇杷露、瑞格列奈片、格列齊特緩釋片、阿卡波糖片、鹽酸帕羅西汀片、鹽酸文拉法辛緩釋膠囊、依折麥布片、黃體酮軟膠囊、一次性使用吸氧管等。企業榮譽：北京生物醫藥產業跨越發展工程 (G20)-行業領軍企...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:07.000Z

**Overall: B (0.35)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 25 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.13% |  |
| Net Profit YoY | -9.20% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.30 |  |
| Dividend Ratio | 1.92% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12.17B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 3.42B |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 12.97% | B |
| Profit Margin | 13.54% | B |
| Gross Margin | 65.43% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.13% | D |
| Net Profit YoY | -9.20% | C |
| Total Assets YoY | 5.65% | B |
| Net Assets YoY | 6.67% | B |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 738.39% | B |
| OCF YoY | -0.13% | D |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.73 | B |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 22.82% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 北京福元醫藥股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "12.97%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "13.54%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "65.43%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.13%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-9.20%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "5.65%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "6.67%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "738.39%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-0.13%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.73",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "22.82%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 興齊眼藥 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恆瑞醫藥 (SH.600276) | A | B | C | A | B | B |
| 04 | 雲南白藥 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 26.29 | 62/222 | 26.29 | 22.98 | 15.48 |
| PB | 3.30 | 145/222 | 3.31 | 2.95 | 2.12 |
| PS (TTM) | 3.56 | 85/222 | 3.56 | 3.13 | 2.21 |
| Dividend Yield | 1.92% | 62/222 | 3.12% | 2.19% | 1.92% |

## References

- [Company Overview](https://longbridge.com/en/quote/601089.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/601089.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/601089.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.